The translational revolution and use of biologics in patients with inflammatory skin diseases
The translational revolution and use of biologics in patients with inflammatory skin diseases
复制标题
DOI：
10.1016/j.jaci.2014.11.015
复制
发表时间：
2015-02-01
影响因子：
14.2
通讯作者：
Guttman-Yassky, Emma
中科院分区：
文献类型：
--
作者：
Noda, Shinji;Krueger, James G.;Guttman-Yassky, Emma
银屑病和特应性皮炎（AD）是以免疫介导的炎症和角质形成细胞分化异常为特征的常见炎症性皮肤病。虽然T细胞浸润是两种疾病的特征，但T细胞极化不同。银屑病是目前转化医学的最佳模型，因为已经开发了许多靶向治疗剂，并且靶向治疗剂的测试已经将银屑病固定为IL-23/T（H）17极化。在AD患者中，虽然治疗开发比银屑病患者晚了大约十年，但目前正在积极开发和测试针对各种免疫轴（T（H）2，T（H）22和IL-23/T（H）17）的靶向治疗。这些临床试验和随后使用人类样本的分子分析将能够阐明极性细胞因子在AD患者中的相对作用。
Psoriasis and atopic dermatitis (AD) are common inflammatory skin diseases characterized by immune-mediated inflammation and abnormal keratinocyte differentiation. Although T-cell infiltration characterizes both diseases, T-cell polarization differs. Psoriasis is currently the best model for translational medicine because many targeted therapeutics have been developed and testing of targeted therapeutics has cemented psoriasis as IL-23/T(H)17 polarized. In patients with AD, although therapeutic development is approximately a decade behind that in patients with psoriasis, there is now active development and testing of targeted therapeutics against various immune axes (T(H)2, T(H)22, and IL-23/T(H)17). These clinical trials and subsequent molecular analyses using human samples will be able to clarify the relative roles of polar cytokines in patients with AD.